This document summarizes recent developments in small molecule epigenetic drugs. It discusses four DNA methyltransferase (DNMT) inhibitors approved by the FDA, including Vidaza and Decitabine. It also discusses two histone deacetylase (HDAC) inhibitors approved, Vorinostat and Romidepsin. Other epigenetic targets discussed include Sirtuins, histone methyltransferases, and protein arginine methyltransferases. The document reviews the development stages of small molecules related to epigenetics and their role in disease development and progression. It provides examples of epigenetic targets disrupted in cancer and structures of common HDAC and other epigenetic inhibitors. In conclusion, it states that HDAC inhibitors